Citadel Advisors
LABD icon

Citadel Advisors’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Citadel Advisors’s Portfolio LABD Stock Details LABD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$965K Buy
59,190
+11,000
+23% +$208K ﹤0.01% 7738
2025
Q4 		$1.01M Buy
48,190
+27,060
+128% +$734K ﹤0.01% 7367
2025
Q3 		$854K Buy
21,130
+1,200
+6% +$69.5K ﹤0.01% 7884
2025
Q2 		$1.49M Sell
19,930
-4,460
-18% -$394K ﹤0.01% 6273
2025
Q1 		$2.3M Sell
24,390
-16,490
-40% -$1.21M ﹤0.01% 5274
2024
Q4 		$2.96M Sell
40,880
-7,030
-15% -$430K ﹤0.01% 4853
2024
Q3 		$2.8M Buy
47,910
+7,990
+20% +$485K ﹤0.01% 4917
2024
Q2 		$2.93M Buy
39,920
+1,860
+5% +$157K ﹤0.01% 4602
2024
Q1 		$2.77M Sell
38,060
-3,820
-9% -$319K ﹤0.01% 4920
2023
Q4 		$4.06M Buy
41,880
+13,490
+48% +$2.62M ﹤0.01% 4104
2023
Q3 		$5.85M Buy
28,390
+7,210
+34% +$1.17M ﹤0.01% 3408
2023
Q2 		$3.04M Buy
21,180
+2,470
+13% +$369K ﹤0.01% 4444
2023
Q1 		$3.86M Sell
18,710
-13,170
-41% -$2.24M ﹤0.01% 4234
2022
Q4 		$5.5M Buy
31,880
+11,220
+54% +$2.3M ﹤0.01% 3695
2022
Q3 		$4.95M Sell
20,660
-100
-0.5% -$23.2K ﹤0.01% 3894
2022
Q2 		$8.08M Buy
20,760
+1,890
+10% +$948K ﹤0.01% 2963
2022
Q1 		$6.62M Buy
18,870
+2,690
+17% +$1.05M ﹤0.01% 3639
2021
Q4 		$4.17M Sell
16,180
-8,505
-34% -$1.96M ﹤0.01% 4661
2021
Q3 		$5.26M Buy
24,685
+6,575
+36% +$1.4M ﹤0.01% 4206
2021
Q2 		$3.5M Buy
18,110
+3,240
+22% +$726K ﹤0.01% 5245
2021
Q1 		$3.23M Buy
14,870
+8,608
+137% +$1.67M ﹤0.01% 5259
2020
Q4 		$1.58M Buy
6,262
+3,602
+135% +$1.37M ﹤0.01% 5862
2020
Q3 		$1.59M Buy
2,660
+1,994
+299% +$1.29M ﹤0.01% 5159
2020
Q2 		$462K Sell
666
-129
-16% -$162K ﹤0.01% 7220
2020
Q1 		$2.24M Buy
795
+182
+30% +$519K ﹤0.01% 3952
2019
Q4 		$1.51M Sell
613
-39
-6% -$139K ﹤0.01% 4857
2019
Q3 		$3.3M Buy
652
+284
+77% +$1.17M ﹤0.01% 3709
2019
Q2 		$1.32M Sell
368
-274
-43% -$1.15M ﹤0.01% 5241
2019
Q1 		$2.36M Buy
642
+360
+128% +$1.74M ﹤0.01% 4183
2018
Q4 		$2.41M Buy
282
+111
+65% +$814K ﹤0.01% 3858
2018
Q3 		$832K Sell
171
-95
-36% -$459K ﹤0.01% 5853
2018
Q2 		$1.38M Buy
+266
New +$1.61M ﹤0.01% 4680
2018
Q1 		– Sell
-7
Closed -$64K – 8547
2017
Q4 		$64K Sell
7
-1
-13% -$9.96K ﹤0.01% 7555
2017
Q3 		$71K Sell
8
-7
-47% -$84.4K ﹤0.01% 7116
2017
Q2 		$208K Sell
15
-2
-12% -$38.4K ﹤0.01% 6509
2017
Q1 		$365K Buy
+17
New +$420K ﹤0.01% 5568
2016
Q4 		– Sell
-12
Closed -$416K – 7581
2016
Q3 		$416K Buy
+12
New +$561K ﹤0.01% 5149

Other funds holding LABD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCM
Capstone Capital Management Hong Kong $224M AUM
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Citadel Advisors's LABD Position: Q1 2026 in Review

Citadel Advisors reduced its Direxion Daily S&P Biotech Bear 3X ETF (LABD) stake by 32% in Q1 2026, selling an estimated $833K and leaving 91,781 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #6715.

Citadel Advisors first reported a position in LABD in Q4 2015 and has held it in 33 quarters since. The position peaked at $5.55M in Q3 2024. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.

  • Citadel Advisors held 91,781 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $1.5M as of Q1 2026.
  • Citadel Advisors sold 43,998 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2026, an estimated $833K.
  • Direxion Daily S&P Biotech Bear 3X ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6715 holding.
  • Citadel Advisors first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q4 2015 and has held it in 33 quarters since.
  • Citadel Advisors's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $5.55M in Q3 2024.
  • 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.